Davies D S
J Int Med Res. 1977;5 Suppl 2:15-9.
The author points out that whilst the total metabolic fate of phenylbutazone in man is better understood, discrepancies between single and multiple dose half-lives, as shown in the studies described, still remain to be explained. It is concluded that the mechanism responsible for limiting the plasma concentration of phenylbutazone when doses are increased requires further study.
作者指出，虽然人们对保泰松在人体内的总代谢归宿有了更好的了解，但如所述研究中所示，单次和多次给药半衰期之间的差异仍有待解释。得出的结论是，当剂量增加时，限制保泰松血浆浓度的机制需要进一步研究。
